Literature DB >> 9605769

The role of type I and type II tumor necrosis factor (TNF) receptors in the ability of TNF-alpha to transduce a proliferative signal in the human megakaryoblastic leukemic cell line Mo7e.

R Y Liu1, C Fan, S Mitchell, Q Chen, J Wu, K S Zuckerman.   

Abstract

We investigated the effects of tumor necrosis factor (TNF) alpha on the human megakaryocytic leukemic cell lines Mo7e, Meg-01, and Dami/HEL. Our data show that both type I and type II TNF receptors (TNF-RI and TNF-RII) are expressed on all of these cells, and TNF-alpha significantly stimulates the proliferation of growth factor-dependent Mo7e cells but not of Meg-01 or Dami/HEL cells, which grow in a factor-independent manner. TNF-alpha serves predominantly as a mitogen for Mo7e cell proliferation and does not induce Mo7e cell differentiation. Coincubation with both TNF-alpha and anti-TNF-alpha neutralizing antibody completely abolishes the TNF-alpha-induced proliferation of Mo7e cells. In bioassays, there is no detectable level of other stimulatory cytokines in conditioned medium from Mo7e cells previously stimulated by TNF-alpha, implying that the stimulatory effect of TNF-alpha on Mo7e cells is derived from the direct action of TNF-alpha rather than via the induction of secondary cytokines by TNF-alpha. Flow cytometric studies demonstrated that TNF-alpha binds to Mo7e cells that have been pretreated with either anti-TNF-RI or anti-TNF-RII neutralizing antibody, but TNF-alpha does not bind to cells pre-exposed to both receptor antibodies. However, the incubation of Mo7e cells with either TNF-RI or TNF-RII neutralizing antibodies or with either soluble TNF-RI or TNF-RII inhibits TNF-alpha-induced cell proliferation, indicating the requirement of interactions with both TNF receptors for the mitogenic activity of TNF-alpha. Furthermore, our data suggest that an alternative signaling pathway may be involved in TNF-alpha-induced Mo7e cell proliferation, because the common mitogen-activated protein kinase (MAPK) and signal transducer and activator of transcription (STAT) signaling pathways activated by other cytokines that induce Mo7e cell proliferation are not activated by TNF-alpha.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9605769

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  6 in total

1.  Phosphatidylcholine-specific phospholipase C and phospholipase D are respectively implicated in mitogen-activated protein kinase and nuclear factor kappaB activation in tumour-necrosis-factor-alpha-treated immature acute-myeloid-leukaemia cells.

Authors:  I Plo; D Lautier; T Levade; H Sekouri; J P Jaffrézou; G Laurent; A Bettaïeb
Journal:  Biochem J       Date:  2000-10-15       Impact factor: 3.857

2.  The diverse roles of the TNF axis in cancer progression and metastasis.

Authors:  Boram Ham; Maria Celia Fernandez; Zarina D'Costa; Pnina Brodt
Journal:  Trends Cancer Res       Date:  2016-01-01

3.  Iron Oxide Nanoparticles for Visualization of Prostate Cancer in MRI.

Authors:  Avan Kader; Jan O Kaufmann; Dilyana B Mangarova; Jana Moeckel; Julia Brangsch; Lisa C Adams; Jing Zhao; Carolin Reimann; Jessica Saatz; Heike Traub; Rebecca Buchholz; Uwe Karst; Bernd Hamm; Marcus R Makowski
Journal:  Cancers (Basel)       Date:  2022-06-13       Impact factor: 6.575

4.  To NFκB or not to NFκB: The Dilemma on How to Inhibit a Cancer Cell Fate Regulator.

Authors:  Daniela Sorriento; Maddalena Illario; Rosa Finelli; Guido Iaccarino
Journal:  Transl Med UniSa       Date:  2012-10-11

5.  Breaking the 'harmony' of TNF-α signaling for cancer treatment.

Authors:  S P Sasi; X Yan; H Enderling; D Park; H-Y Gilbert; C Curry; C Coleman; L Hlatky; G Qin; R Kishore; D A Goukassian
Journal:  Oncogene       Date:  2011-12-12       Impact factor: 9.867

6.  Tumor necrosis factor-α induces prostate cancer cell migration in lymphatic metastasis through CCR7 upregulation.

Authors:  Aerken Maolake; Kouji Izumi; Ariunbold Natsagdorj; Hiroaki Iwamoto; Suguru Kadomoto; Tomoyuki Makino; Renato Naito; Kazuyoshi Shigehara; Yoshifumi Kadono; Kaoru Hiratsuka; Guzailinuer Wufuer; Kent L Nastiuk; Atsushi Mizokami
Journal:  Cancer Sci       Date:  2018-04-29       Impact factor: 6.716

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.